Previous 10 | Next 10 |
2024-01-24 04:31:39 ET Summary Sarepta Therapeutics is a biopharmaceutical company focused on developing gene therapy and RNA-targeted treatments for rare diseases such as Duchenne muscular dystrophy and Limb-girdle muscular dystrophy. The company's FDA-approved products, includin...
2024-01-22 17:47:39 ET Sarepta Therapeutics (NASDAQ: SRPT) saw a lot of love from the market as the trading week kicked off on Monday. Investors pushed the stock almost 5% higher in price, a move due in no small part to an analyst's considerable price target raise. Sarepta's gain tr...
2024-01-22 13:43:30 ET Summary Sarepta's ELEVIDYS faces a critical FDA decision; an expanded label could significantly widen market reach, targeting all DMD patients. Strong Q3 performance with impressive revenue and EPS; financial health shows robust short-term standing but long-...
2024-01-20 10:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A drastic shift in inv...
2024-01-16 23:01:41 ET Summary IND SGT-003 gene therapy cleared for phase 1/2 testing: First patient dosing expected late Q1 2024 with biomarker/functional data expected Q3 of 2024. The global Duchenne Muscular Dystrophy drugs market is expected to reach $27.4 billion by 2030. ...
2024-01-16 10:41:01 ET More on Sarepta Therapeutics Sarepta Therapeutics: Strong Q3 Earnings Help Offset Overblown Clinical Data Concerns Sarepta Therapeutics, Inc. (SRPT) Q3 2023 Earnings Call Transcript Sarepta Therapeutics, Inc. 2023 Q3 - Results - Earnings Call P...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that screening is underway in Study SRP-9003-301. Also known as EMERGENE, Study 9003-301 is a Phase 3, multi-national, open-label study of SRP-9003 (bidridistrogene xeboparvovec) ...
2024-01-10 10:30:02 ET RBC Capital analyst issues UNDERPERFORM recommendation for SRPT on January 10, 2024 11:00AM ET. The previous analyst recommendation was Underperform. SRPT was trading at $117.6 at issue of the analyst recommendation. The overall analyst consensus :...
2024-01-10 10:30:02 ET Wedbush analyst issues BUY recommendation for SRPT on January 10, 2024 11:00AM ET. The previous analyst recommendation was Buy. SRPT was trading at $117.6 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 0.79% on the day to $107.67. Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery an...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
2024-07-08 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...